Free tool
Oncology stocks
We cover 154 companies grouped under the Oncology theme. The median market value in the group is $48.19M. Across the group, the median move over the past trading day is −0.23%. 39% of the 150 with a 200-day average trade above it. Price change over the past year runs from −77.1% to +149.8% across the middle 80 percent of the group, with a median of −19.0%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
154 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| AZN.L | AstraZeneca PLC | 12,476.00 GBP | −5.00% | −8.20% | +5.65% |
| AZN | AstraZeneca PLC | $166.27 | −3.60% | −8.27% | +5.09% |
| A1ZN34.SA | AstraZeneca PLC | 143.10 BRL | −2.15% | −13.50% | +0.13% |
| BMY | Bristol-Myers Squibb Company | $67.57 | +6.24% | +27.70% | +47.01% |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | 6,953.00 JPY | −1.64% | −18.35% | +9.21% |
| RVMD | Revolution Medicines, Inc. | $215.44 | +17.18% | +172.64% | +466.35% |
| ONC | BeOne Medicines AG | $375.80 | +13.72% | +20.83% | +25.21% |
| 4568.T | Daiichi Sankyo Company, Limited | 2,874.50 JPY | −0.42% | −17.47% | −17.94% |
| BNTX | BioNTech SE | $112.56 | +21.75% | +16.41% | +9.27% |
| INCY | Incyte Corporation | $128.12 | −1.39% | +26.33% | +51.01% |
| GMAB | Genmab A/S | $33.75 | +16.38% | +6.07% | +36.20% |
| IPN.PA | Ipsen S.A. | 166.00 EUR | +1.41% | +42.98% | +40.80% |
| EXEL | Exelixis, Inc. | $56.10 | −0.73% | +28.73% | +45.68% |
| 0IJO.L | Exelixis, Inc. | $56.81 | +4.53% | +31.50% | +50.53% |
| SMMT | Summit Therapeutics Inc. | $14.23 | +13.39% | −18.78% | −42.63% |
| NUVL | Nuvalent Inc | $123.96 | 0.00% | +22.93% | +62.83% |
| 4528.T | Ono Pharmaceutical Co., Ltd. | 2,462.50 JPY | −1.16% | +14.31% | +54.43% |
| CGON | CG Oncology, Inc. | $78.42 | +7.99% | +87.65% | +196.15% |
| ERAS | Erasca, Inc. | $19.15 | +5.45% | +433.43% | +1112.03% |
| E2XE34.SA | Exelixis, Inc. | 137.40 BRL | −2.25% | +23.92% | +23.92% |
| LNTH | Lantheus Holdings, Inc. | $100.82 | −1.77% | +49.87% | +77.38% |
| COGT | Cogent Biosciences, Inc. | $36.72 | −9.71% | +5.70% | +196.85% |
| CELC | Celcuity Inc. | $95.08 | +15.30% | −5.44% | +90.31% |
| 000100.KS | Yuhan Corporation | 83,100.00 KRW | +18.21% | −25.94% | −27.54% |
| ELVN | Enliven Therapeutics, Inc. | $60.87 | +13.22% | +291.67% | +194.32% |
| TNGX | Tango Therapeutics, Inc. | $25.47 | −4.43% | +185.22% | +269.13% |
| RLAY | Relay Therapeutics, Inc. | $19.46 | +6.40% | +137.90% | +445.10% |
| RCUS | Arcus Biosciences, Inc. | $30.76 | +13.72% | +32.07% | +191.29% |
| 000105.KS | Yuhan Corporation | 70,500.00 KRW | +19.09% | −30.38% | −32.04% |
| TLX.AX | Telix Pharmaceuticals Limited | 15.68 AUD | +8.14% | +38.03% | +4.88% |
| TLX | Telix Pharmaceuticals Limited | $11.13 | +9.22% | +46.06% | −8.02% |
| IMNM | Immunome, Inc. | $28.75 | +23.82% | +38.09% | +188.94% |
| SLS | SELLAS Life Sciences Group, Inc. | $13.73 | +36.08% | +215.63% | +615.10% |
| NRIX | Nurix Therapeutics, Inc. | $26.71 | +10.60% | +47.90% | +179.69% |
| NUVB | Nuvation Bio Inc. | $6.96 | +4.04% | −18.88% | +135.93% |
| NBTX | Nanobiotix S.A. | $44.50 | +17.66% | +101.08% | +394.99% |
| URGN | UroGen Pharma Ltd. | $45.94 | +12.38% | +102.29% | +135.11% |
| HCM.L | HUTCHMED (China) Limited | 179.00 GBP | +3.17% | −12.25% | −18.08% |
| HCM | HUTCHMED (China) Limited | $12.35 | +10.27% | −9.52% | −17.45% |
| NVCR | NovoCure Limited | $17.89 | +9.69% | +36.36% | +50.21% |
| NANO.PA | Nanobiotix S.A. | 35.74 EUR | +8.43% | +88.11% | +358.21% |
| JATT | JATT II Acquisition Corp. | $12.01 | +7.81% | +14.38% | +14.38% |
| ACRV | Acrivon Therapeutics, Inc. | $2.08 | +35.06% | −15.45% | +52.94% |
| 4579.T | RaQualia Pharma Inc. | 568.00 JPY | +25.39% | −41.56% | +3.46% |
| OSE.PA | OSE Immunotherapeutics SA | 3.21 EUR | −0.19% | −39.40% | −47.94% |
| MAIA | MAIA Biotechnology, Inc. | $1.39 | +12.10% | −13.13% | −15.76% |
| VRCA | Verrica Pharmaceuticals Inc. | $4.91 | −9.07% | −40.84% | −13.25% |
| 0QW5.L | Heidelberg Pharma AG | 2.46 EUR | 0.00% | −2.38% | −33.15% |
| CTOR | Citius Oncology, Inc. | $0.79 | +45.49% | −27.12% | −62.34% |
| POLB.L | Poolbeg Pharma PLC | 8.60 GBP | +36.51% | +120.51% | +164.62% |
| 4888.T | Stella Pharma Corporation | 353.00 JPY | +18.06% | +66.51% | −11.75% |
| ELTX | Elicio Therapeutics, Inc. | $2.98 | +1.02% | −62.98% | −71.29% |
| APLM | Apollomics, Inc. | $26.20 | +43.80% | +35.75% | +320.55% |
| OSTX | OS Therapies Incorporated | $1.65 | +10.00% | +23.13% | −34.00% |
| CRDF | Cardiff Oncology, Inc. | $0.98 | +20.01% | −63.00% | −54.65% |
| PLRX | Pliant Therapeutics, Inc. | $1.16 | +8.41% | −7.20% | −31.36% |
| XBIT | XBiotech Inc. | $2.31 | +1.76% | −2.94% | −33.62% |
| PMVP | PMV Pharmaceuticals, Inc. | $1.31 | +19.09% | +6.50% | −7.75% |
| RNXT | RenovoRx, Inc. | $1.49 | +64.28% | +78.44% | +61.08% |
| BOLD | Boundless Bio, Inc. | $2.92 | +18.02% | +138.93% | +155.70% |
| MAAT.PA | MaaT Pharma SA | 3.04 EUR | +8.96% | −45.52% | −33.91% |
| XLO | Xilio Therapeutics, Inc. | $9.05 | −1.09% | −3.81% | −5.63% |
| HRTX | Heron Therapeutics, Inc. | $0.31 | −36.29% | −75.22% | −77.04% |
| 4564.T | OncoTherapy Science, Inc. | 21.00 JPY | +5.00% | 0.00% | −25.00% |
| IMMP | Immutep Limited | $0.38 | −2.56% | −87.12% | −77.11% |
| 0OCQ.L | Transgene SA | 0.81 EUR | −0.25% | −16.36% | −22.31% |
| ATX.AX | Amplia Therapeutics Limited | 0.15 AUD | +11.54% | −14.71% | −14.71% |
| IMM.AX | Immutep Limited | 0.05 AUD | +8.51% | −88.14% | −79.18% |
| 4572.T | Carna Biosciences, Inc. | 402.00 JPY | +37.67% | 0.00% | +81.90% |
| TIL | Instil Bio, Inc. | $7.83 | +7.41% | −30.52% | −72.04% |
| 0RAD.L | OSE Immunotherapeutics SA | 3.19 EUR | −1.30% | −39.91% | −48.50% |
| 4597.T | Solasia Pharma K.K. | 30.00 JPY | +3.45% | +7.14% | −18.92% |
| CANTA.ST | Cantargia AB (publ) | 1.91 SEK | +3.24% | −53.64% | −27.38% |
| PTX.AX | Prescient Therapeutics Limited | 0.07 AUD | −17.28% | −19.28% | +63.41% |
| IBO | Impact BioMedical Inc. | $0.44 | +2.35% | −15.20% | −24.12% |
| COIL.L | Coiled Therapeutics plc | 9.50 GBP | −9.52% | −20.83% | −26.92% |
| BKHA | Black Hawk Acquisition Corporation | $11.85 | −2.09% | +5.31% | +7.70% |
| SVE.WA | Synthaverse S.A. | 3.06 PLN | +9.29% | −20.21% | −36.25% |
| 4594.T | BrightPath Biotherapeutics Co., Ltd. | 53.00 JPY | +15.22% | +8.16% | −39.08% |
| MOC.WA | Molecure S.A. | 6.03 PLN | −2.58% | −8.08% | −22.39% |
| CNTX | Context Therapeutics Inc. | $0.42 | −28.31% | −72.66% | −50.73% |
| 206A.T | PRISM BioLab Co.,LTD | 170.00 JPY | +18.06% | +5.59% | −5.56% |
| SNT.AX | Syntara Limited | 0.03 AUD | +22.73% | −20.59% | +1.89% |
| BCT.TO | BriaCell Therapeutics Corp. | 5.62 CAD | +15.64% | −42.77% | −46.48% |
| BCTX | BriaCell Therapeutics Corp. | $4.03 | +16.14% | −43.79% | −46.97% |
| 190A.T | CHORDIA THERAPEUTICS INC | 72.00 JPY | −1.37% | −35.71% | −59.32% |
| ATNM | Actinium Pharmaceuticals, Inc. | $1.01 | +16.49% | −26.28% | −42.61% |
| MDNA.TO | Medicenna Therapeutics Corp. | 0.47 CAD | +32.39% | −53.00% | −56.48% |
| 4582.T | SymBio Pharmaceuticals Limited | 63.00 JPY | −4.55% | −30.00% | −57.43% |
| BYSI | BeyondSpring Inc. | $0.69 | −41.77% | −57.14% | −62.09% |
| CVM | CEL-SCI Corporation | $1.61 | +34.17% | −68.74% | −87.65% |
| NNG.WA | NanoGroup S.A. | 2.38 PLN | −4.80% | −11.19% | −17.36% |
| LTRN | Lantern Pharma Inc. | $2.18 | −16.15% | −29.90% | −46.17% |
| NXTC | NextCure, Inc. | $5.83 | +7.56% | −56.10% | +11.37% |
| EVAX | Evaxion A/S | $3.24 | +15.71% | −31.21% | +6.93% |
| PSTV | Plus Therapeutics Inc | $3.84 | +2.07% | −72.59% | −68.67% |
| ATOS | Atossa Therapeutics, Inc. | $2.65 | +9.50% | −71.96% | −76.75% |
| MRKR | Marker Therapeutics, Inc. | $1.45 | +22.88% | −5.84% | +54.26% |
| CLRB | Cellectar Biosciences, Inc. | $2.54 | +1.60% | −26.80% | −47.30% |
| CCM | Concord Medical Services Holdings Limited | $4.96 | +7.83% | +16.16% | −10.47% |
| ALLR | Allarity Therapeutics, Inc. | $1.34 | +13.56% | +17.54% | −15.72% |
| DEX.ST | Dextech Medical AB | 10.30 SEK | −0.96% | +11.35% | +26.38% |
| NOX.AX | Noxopharm Limited | 0.09 AUD | −2.17% | −4.26% | −10.00% |
| ALTME.PA | TME Pharma N.V. | 0.13 EUR | +113.11% | +88.41% | +25.97% |
| TPST | Tempest Therapeutics, Inc. | $1.08 | +24.00% | −63.39% | −89.96% |
| AKTX | Akari Therapeutics, Plc | $9.10 | +7.95% | −21.55% | −72.42% |
| ABERA.ST | Abera Bioscience AB | 8.18 SEK | −2.62% | +13.61% | +1.61% |
| B8FK.DE | Biofrontera AG | 2.53 EUR | −0.78% | −0.78% | −3.07% |
| 4882.T | Perseus Proteomics Inc. | 149.00 JPY | +4.93% | −34.65% | −56.56% |
| MDCX | Medicus Pharma Ltd. | $0.27 | −4.11% | −83.22% | −86.77% |
| RAD.AX | Radiopharm Theranostics Limited | 0.01 AUD | −28.57% | −60.00% | −63.64% |
| CTXR | Citius Pharmaceuticals, Inc. | $0.58 | +15.88% | −31.95% | −57.88% |
| LSTA | Lisata Therapeutics, Inc. | $1.74 | +50.00% | −11.22% | −30.40% |
| INTS | Intensity Therapeutics, Inc. | $4.53 | −0.44% | −55.48% | −40.00% |
| ACTI.ST | Active Biotech AB (publ) | 5.50 SEK | +6.38% | +19.57% | −62.00% |
| PHIO | Phio Pharmaceuticals Corp. | $1.20 | +18.81% | +10.09% | −40.89% |
| GTBP | GT Biopharma, Inc. | $0.29 | −8.49% | −64.49% | −74.55% |
| BLRX | BioLineRx Ltd. | $2.70 | −3.91% | −3.57% | −26.63% |
| TOVX | Theriva Biologics, Inc. | $0.24 | +15.81% | −6.46% | −42.10% |
| LNAI | Lunai Bioworks Inc. | $2.20 | −1.79% | −71.71% | −89.34% |
| PUR.WA | MultiQure S.A. | 3.05 PLN | +40.23% | −25.43% | −55.05% |
| 4598.T | Delta-Fly Pharma, Inc. | 104.00 JPY | +9.47% | −80.92% | −81.75% |
| IMNN | Imunon, Inc. | $1.63 | +6.54% | −58.73% | −73.10% |
| CNSP | CNS Pharmaceuticals, Inc. | $5.44 | +7.30% | +2.64% | −13.51% |
| AIM | AIM ImmunoTech Inc. | $0.25 | +4.17% | −78.34% | −89.69% |
| PAB.AX | Patrys Limited | 0.03 AUD | −23.08% | +11.11% | −14.29% |
| BOLT | Bolt Biotherapeutics, Inc. | $3.92 | −2.49% | −32.30% | −26.73% |
| CANF | Can-Fite BioPharma Ltd. | $3.32 | +5.06% | −24.55% | −74.85% |
| ALOPM.PA | Oncodesign Precision Medicine Société anonyme | 0.32 EUR | +2.57% | −18.41% | −19.44% |
| CHOSA.ST | Chosa Oncology AB | 0.73 SEK | −14.15% | −20.00% | −9.00% |
| ITOC | iTonic Holdings Ltd. | $0.29 | +11.89% | −33.23% | −59.75% |
| NCNA | NuCana plc | $1.53 | +18.60% | −57.97% | −52.78% |
| LIMN | Liminatus Pharma, Inc. | $4.41 | +4140.38% | +587.99% | +46.03% |
| PCSA | Processa Pharmaceuticals, Inc. | $2.13 | −30.16% | −27.30% | −60.00% |
| KAPA | Kairos Pharma, Ltd. | $0.26 | −15.58% | −64.33% | −77.97% |
| NFX.L | Nuformix plc | 0.16 GBP | +6.71% | −46.10% | +80.68% |
| 0GP7.L | Medivir AB (publ) | 2.03 SEK | +6.77% | +345.66% | +1.60% |
| PER.AX | PERCHERON FPO [PER] | 0.01 AUD | +66.67% | −47.37% | −54.55% |
| BCAB | BioAtla, Inc. | $3.12 | −11.61% | −88.31% | −86.04% |
| HCWB | HCW Biologics Inc. | $2.70 | +4.45% | +141.07% | −55.15% |
| APS.TO | Aptose Biosciences Inc | 2.40 CAD | 0.00% | +18.81% | +50.00% |
| OSRH | OSR Health, Inc. | $0.17 | −63.24% | −71.48% | −80.93% |
| RDHL | RedHill Biopharma Ltd. | $0.62 | −15.71% | −40.26% | −53.74% |
| DBP-B.ST | Double Bond Pharmaceutical International AB (publ) | 0.16 SEK | +30.42% | +16.79% | +11.79% |
| CLDI | Calidi Biotherapeutics, Inc. | $1.35 | −21.14% | +14.41% | −19.16% |
| GOVX | GeoVax Labs, Inc. | $0.63 | −13.33% | −87.82% | −96.67% |
| ARTL | Artelo Biosciences, Inc. | $0.71 | −19.25% | −81.35% | −97.37% |
| IVX.AX | Invion Limited | 0.04 AUD | −18.18% | −61.29% | −72.31% |
| PPBT | Purple Biotech Ltd | $1.73 | +26.28% | −73.79% | −92.21% |
| VAL.L | ValiRx plc | 0.16 GBP | +3.33% | −57.53% | −73.04% |
| NXTS | Nexentis Technologies Inc. | $1.88 | +21.29% | −83.11% | −96.40% |
| PPCB | Propanc Biopharma, Inc. | $1.07 | −11.57% | −92.51% | −98.54% |
| NX1.AX | Nexalis Therapeutics Limited | 0.01 AUD | 0.00% | −50.00% | −50.00% |
| PTP.DE | Pentixapharm Holding AG | 1.85 EUR | −5.61% | +20.13% | +5.47% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.